Kevin W Garey Selected Research

Anti-Bacterial Agents (Antibiotics)

2/2024	A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response.
12/2023	Fecal Pharmacokinetics and Gut Microbiome Effects of Oral Omadacycline versus Vancomycin in Healthy Volunteers.
7/2023	Redefining Clostridioides difficile infection antibiotic response and clinical outcomes.
2/2023	Emerging Options for the Prevention and Management of Clostridioides difficile Infection.
1/2023	Risk Factors Associated with Severe Clostridioides difficile Infection in Patients with Cancer.
1/2023	Gut microbiota changes associated with Clostridioides difficile infection and its various treatment strategies.
1/2023	The Novel DNA Binding Mechanism of Ridinilazole, a Precision Clostridiodes difficile Antibiotic.
1/2022	Functional and Metagenomic Evaluation of Ibezapolstat for Early Evaluation of Anti-Recurrence Effects in Clostridioides difficile Infection.
11/2021	Antibiotic Therapies for Clostridioides difficile Infection in Children.
10/2021	Corticosteroids Do Not Increase the Likelihood of Primary Clostridioides difficile Infection in the Setting of Broad-Spectrum Antibiotic Use.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kevin W Garey Research Topics

Disease

39	Clostridium Infections 02/2024 - 05/2010
27	Infections 02/2024 - 01/2003
19	Diarrhea 03/2023 - 04/2005
14	Candidemia 01/2024 - 05/2006
8	Communicable Diseases (Infectious Diseases) 11/2021 - 08/2007
6	Bacteremia 01/2018 - 08/2006
5	Invasive Candidiasis 01/2024 - 05/2006
5	Neoplasms (Cancer) 01/2023 - 07/2006
5	Inflammation (Inflammations) 01/2020 - 05/2003
3	Dysbiosis 02/2024 - 01/2023
3	Body Weight (Weight, Body) 01/2020 - 06/2012
3	Drug-Related Side Effects and Adverse Reactions 01/2019 - 04/2005
3	Acquired Immunodeficiency Syndrome (AIDS) 01/2013 - 05/2010
3	Cholera 01/2013 - 05/2010
2	Leukocytosis (Pleocytosis) 12/2023 - 11/2015
2	Bacterial Pneumonia 02/2023 - 01/2023
2	Gastrointestinal Diseases (Functional Gastrointestinal Disorders) 10/2021 - 09/2014
2	Gram-Negative Bacterial Infections 08/2021 - 03/2020
2	Vitamin D Deficiency 01/2021 - 05/2012
2	Nausea 04/2016 - 01/2004
2	Chronic Obstructive Pulmonary Disease (COPD) 07/2015 - 01/2004
2	Systemic candidiasis 04/2015 - 06/2014
2	Cystic Fibrosis (Mucoviscidosis) 02/2012 - 01/2003
2	Cross Infection (Nosocomial Infection) 07/2011 - 07/2007
2	Surgical Wound 06/2008 - 09/2006
2	Human Influenza (Influenza) 05/2007 - 02/2004
2	Surgical Wound Infection 09/2006 - 03/2006
2	Asthma (Bronchial Asthma) 01/2004 - 01/2003
1	Fever (Fevers) 12/2023
1	Osteomyelitis 10/2022
1	Hematologic Neoplasms (Hematological Malignancy) 07/2021
1	Autoimmune Diseases (Autoimmune Disease) 07/2021
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 07/2021
1	Cryptosporidiosis 01/2021
1	Cytomegalovirus Infections (Inclusion Disease) 01/2021
1	Intraabdominal Infections 10/2020
1	Atrophy 01/2020
1	Autolysis 01/2020
1	Enteritis 01/2020
1	Necrosis 01/2020
1	Colitis 01/2019

Drug/Important Bio-Agent (IBA)

27	Anti-Bacterial Agents (Antibiotics)IBA 02/2024 - 01/2003
11	Vancomycin FDA LinkGeneric 02/2024 - 03/2006
7	EchinocandinsIBA 01/2024 - 07/2012
6	Fluconazole (Zonal)FDA LinkGeneric 01/2018 - 07/2006
6	Rifaximin (L 105)FDA Link 06/2013 - 04/2005
5	FidaxomicinIBA 01/2021 - 01/2016
5	bezlotoxumabIBA 01/2021 - 01/2019
4	ridinilazoleIBA 02/2024 - 08/2016
4	Nucleic AcidsIBA 03/2023 - 01/2022
4	Biomarkers (Surrogate Marker)IBA 01/2023 - 01/2004
4	Metronidazole (Metric)FDA LinkGeneric 11/2021 - 10/2015
4	RifamycinsIBA 06/2013 - 04/2005
3	CreatinineIBA 12/2023 - 06/2012
3	FluoroquinolonesIBA 12/2023 - 01/2017
3	InterleukinsIBA 03/2023 - 08/2007
3	Carbapenems (Carbapenem Antibiotics)IBA 08/2021 - 07/2007
3	Anti-Infective Agents (Microbicides)IBA 01/2021 - 06/2008
3	ChloridesIBA 01/2013 - 05/2010
3	Chloride Channels (Chloride Channel)IBA 01/2013 - 05/2010
3	crofelemer (SP-303)IBA 01/2013 - 05/2010
2	CytokinesIBA 03/2023 - 01/2023
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 03/2023 - 01/2023
2	VaccinesIBA 02/2023 - 02/2004
2	AntibodiesIBA 01/2023 - 01/2015
2	Micafungin (FK463)FDA Link 01/2023 - 09/2015
2	IbezapolstatIBA 01/2022 - 01/2022
2	Adrenal Cortex Hormones (Corticosteroids)IBA 10/2021 - 01/2004
2	meropenem and vaborbactamIBA 08/2021 - 03/2020
2	hydroxide ionIBA 01/2021 - 05/2012
2	Ceftriaxone (Ceftriaxon)FDA LinkGeneric 01/2020 - 12/2018
2	Caspofungin (Cancidas)FDA Link 01/2018 - 09/2015
2	Antifungal AgentsIBA 06/2014 - 07/2012
2	Interleukin-8 (Interleukin 8)IBA 12/2010 - 08/2007
1	Bile Acids and Salts (Bile Acids)IBA 02/2024
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 03/2023
1	Bisbenzimidazole (Hoechst 33258)IBA 01/2023
1	omadacyclineIBA 01/2023
1	AntitoxinsIBA 01/2023
1	Bacterial DNAIBA 01/2022
1	SteroidsIBA 07/2021
1	eravacyclineIBA 10/2020
1	muramyl- NAc- (pentapeptide)pyrophosphoryl- undecaprenolIBA 01/2020
1	Actins (F Actin)IBA 01/2020
1	Alanine (L-Alanine)FDA Link 01/2020
1	PotassiumIBA 01/2020
1	Potassium Chloride FDA LinkGeneric 01/2020
1	Serine (L-Serine)FDA Link 01/2020
1	Monoclonal AntibodiesIBA 01/2019
1	MucinsIBA 01/2019
1	Polysaccharides (Glycans)IBA 01/2019

Therapy/Procedure

28	Therapeutics 12/2023 - 01/2004
7	Drug Therapy (Chemotherapy) 01/2021 - 06/2008
4	Length of Stay 01/2019 - 08/2006
3	Fecal Microbiota Transplantation 01/2023 - 04/2013
1	Transplantation 03/2023
1	Mechanical Ventilators (Ventilator) 02/2023
1	Bioreactors (Bioreactor) 01/2021
1	Injections 01/2020
1	Patient Discharge 01/2019